The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

被引:27
作者
Schmitz, Susanne [1 ]
Maguire, Aine [2 ,3 ]
Morris, James [4 ]
Ruggeri, Kai [3 ,14 ]
Haller, Elisa [5 ]
Kuhn, Isla [6 ]
Leahy, Joy [7 ]
Homer, Natalia [4 ]
Khan, Ayesha [8 ]
Bowden, Jack [9 ]
Buchanan, Vanessa [4 ]
O'Dwyer, Michael [10 ]
Cook, Gordon [11 ,12 ]
Walsh, Cathal [13 ]
机构
[1] Luxembourg Inst Hlth, Dept Populat Hlth, Strassen, Luxembourg
[2] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland
[3] Univ Cambridge, Dept Psychol, Cambridge, England
[4] Cogentia Healthcare Consulting, Cambridge, England
[5] Univ Zurich, Dept Psychol, Zurich, Switzerland
[6] Univ Cambridge, Univ Lib Med Lib, Cambridge, England
[7] Trinity Coll Dublin, Dept Comp Sci & Stat, Dublin, Ireland
[8] Univ Exeter, Exeter, Devon, England
[9] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England
[10] NUI Galway, Dept Med, Galway, Ireland
[11] St James Univ Hosp, Haematol & Myeloma Studies, Leeds, W Yorkshire, England
[12] St James Univ Hosp, NIHR MIC DEL, Leeds, W Yorkshire, England
[13] Univ Limerick, Hlth Res Inst, Limerick, Ireland
[14] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2018年 / 18卷
关键词
Network meta-analysis; Single armed studies; Evidence synthesis; Relapsed or refractory myeloma; LENALIDOMIDE PLUS DEXAMETHASONE; ADJUSTED INDIRECT COMPARISONS; MIXED TREATMENT COMPARISONS; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; PROPENSITY SCORE; REFRACTORY MYELOMA; TREATMENT OUTCOMES; BORTEZOMIB; THERAPY;
D O I
10.1186/s12874-018-0509-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Network meta-analysis (NMA) allows for the estimation of comparative effectiveness of treatments that have not been studied in head-to-head trials; however, relative treatment effects for all interventions can only be derived where available evidence forms a connected network. Head-to-head evidence is limited in many disease areas, regularly resulting in disconnected evidence structures where a large number of treatments are available. This is also the case in the evidence of treatments for relapsed or refractory multiple myeloma. Methods: Randomised controlled trials (RCTs) identified in a systematic literature review form two disconnected evidence networks. Standard Bayesian NMA models are fitted to obtain estimates of relative effects within each network. Observational evidence was identified to fill the evidence gap. Single armed trials are matched to act as each other's control group based on a distance metric derived from covariate information. Uncertainty resulting from including this evidence is incorporated by analysing the space of possible matches. Results: Twenty five randomised controlled trials form two disconnected evidence networks; 12 single armed observational studies are considered for bridging between the networks. Five matches are selected to bridge between the networks. While significant variation in the ranking is observed, daratumumab in combination with dexamethasone and either lenalidomide or bortezomib, as well as triple therapy of carfilzomib, ixazomib and elozumatab, in combination with lenalidomide and dexamethasone, show the highest effects on progression free survival, on average. Conclusions: The analysis shows how observational data can be used to fill gaps in the existing networks of RCT evidence; allowing for the indirect comparison of a large number of treatments, which could not be compared otherwise. Additional uncertainty is accounted for by scenario analyses reducing the risk of over confidence in interpretation of results.
引用
收藏
页数:18
相关论文
共 50 条
[31]   Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis [J].
Facon, Thierry ;
San-Miguel, Jesus ;
Dimopoulos, Meletios A. ;
Mateos, Maria-Victoria ;
Cavo, Michele ;
van Beekhuizen, Sophie ;
Yuan, Zijiao ;
Mendes, Joao ;
Lam, Annette ;
He, Jianming ;
Ammann, Eric ;
Kumar, Shaji .
ADVANCES IN THERAPY, 2022, 39 (05) :1976-1992
[32]   EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma [J].
Landgren, Ola ;
Prior, Thomas J. ;
Masterson, Tara ;
Heuck, Christoph ;
Bueno, Orlando F. ;
Dash, Ajeeta B. ;
Einsele, Hermann ;
Goldschmidt, Hartmut ;
Knop, Stefan ;
Li, Cong ;
Mellqvist, Ulf-Henrik ;
McFadden, Ian ;
Oprea, Corina ;
Ross, Jeremy A. ;
Talpes, Mihaela ;
Hydren, Jay R. ;
Ahlstrom, Jennifer M. ;
Kazandjian, Dickran ;
Weinhold, Niels ;
Zhang, Rick ;
Stetler-Stevenson, Maryalice ;
Marti, Gerald ;
Devlin, Sean M. .
BLOOD, 2024, 144 (04) :359-367
[33]   Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis [J].
Leonardo Javier Arcuri ;
Andre Dias Americo .
Annals of Hematology, 2021, 100 :725-734
[34]   Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis [J].
Arcuri, Leonardo Javier ;
Americo, Andre Dias .
ANNALS OF HEMATOLOGY, 2021, 100 (03) :725-734
[35]   Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact [J].
Leahy, Joy ;
Thom, Howard ;
Jansen, Jeroen P. ;
Gray, Emma ;
O'Leary, Aisling ;
White, Arthur ;
Walsh, Cathal .
STATISTICS IN MEDICINE, 2019, 38 (14) :2505-2523
[36]   Bortezomib-based treatment for multiple myeloma patients with renal impairment A systematic review and meta-analysis of observational studies [J].
Zhu, Wangiu ;
Chen, Wenming .
MEDICINE, 2016, 95 (46)
[37]   Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials [J].
Dhakal, Binod ;
Narra, Ravi K. ;
Giri, Smith ;
Szabo, Aniko ;
Smunt, Timothy L. ;
Ghose, Sanjoy ;
Pathak, Lakshmi Kant ;
Aryal, Madan ;
Hamadani, Mehdi ;
Chhabra, Saurabh ;
Janz, Siegfried ;
D'Souza, Anita ;
Hari, Parameswaran N. .
CANCER, 2020, 126 (12) :2791-2801
[38]   Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials [J].
Zou, Yandun ;
Ma, Xiaoyan ;
Yu, Haiying ;
Hu, Chunling ;
Fan, Limei ;
Ran, Xuehong .
ONCOTARGET, 2017, 8 (24) :39805-39817
[39]   Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant [J].
Botta, Cirino ;
Gigliotta, Emilia ;
Paiva, Bruno ;
Anselmo, Rita ;
Santoro, Marco ;
Otero, Paula Rodriguez ;
Carlisi, Melania ;
Conticello, Concetta ;
Romano, Alessandra ;
Solimando, Antonio Giovanni ;
Cerchione, Claudio ;
Da Via, Matteo ;
Bolli, Niccolo ;
Correale, Pierpaolo ;
Di Raimondo, Francesco ;
Gentile, Massimo ;
San Miguel, Jesus ;
Siragusa, Sergio .
HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) :987-998
[40]   Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis [J].
Huang, Xiaohua ;
Zhou, Jia ;
Qian, Yuxiao ;
He, Jing ;
Yang, Lu ;
Wang, Zhigang ;
Wei, Diu ;
Li, Mengjie ;
Ma, Wei ;
Lang, Haiyan .
SYSTEMATIC REVIEWS, 2025, 14 (01)